Andreas Argyrides
Stock Analyst at Wedbush
(4.12)
# 616
Out of 4,413 analysts
85
Total ratings
48.65%
Success rate
14.07%
Average return
Main Sectors:
Top Industries:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLTX MoonLake Immunotherapeutics | Reiterates: Outperform | $92 | $42.84 | +114.75% | 13 | Mar 13, 2024 | |
| SPRY ARS Pharmaceuticals | Reiterates: Outperform | $19 | $9.33 | +103.64% | 9 | Mar 11, 2024 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $4 → $9 | $3.37 | +167.46% | 4 | Mar 7, 2024 | |
| GOSS Gossamer Bio | Reiterates: Outperform | $6 | $0.71 | +748.06% | 7 | Mar 6, 2024 | |
| OCS Oculis Holding AG | Reiterates: Outperform | $29 | $12.85 | +125.68% | 3 | Mar 6, 2024 | |
| RGNX REGENXBIO | Reiterates: Neutral | $21 | $16.20 | +29.63% | 4 | Feb 28, 2024 | |
| SRPT Sarepta Therapeutics | Reiterates: Outperform | $224 | $130.90 | +71.12% | 4 | Feb 20, 2024 | |
| PCRX Pacira BioSciences | Reiterates: Outperform | $57 | $26.95 | +111.50% | 2 | Feb 8, 2024 | |
| ASND Ascendis Pharma | Maintains: Outperform | $207 → $225 | $141.01 | +59.56% | 8 | Feb 8, 2024 | |
| RANI Rani Therapeutics Holdings | Reiterates: Outperform | $8 | $6.37 | +25.59% | 3 | Feb 6, 2024 | |
| LQDA Liquidia | Reiterates: Underperform | $3 | $13.17 | -77.22% | 5 | Dec 21, 2023 | |
| UBX Unity Biotechnology | Upgrades: Outperform | n/a | $1.56 | - | 6 | Nov 16, 2023 | |
| KROS Keros Therapeutics | Reiterates: Outperform | $86 | $57.72 | +49.00% | 4 | Nov 13, 2023 | |
| IMUX Immunic | Maintains: Outperform | $5 → $7 | $1.30 | +438.46% | 3 | Oct 10, 2023 | |
| MNKD MannKind | Initiates: Outperform | $10 | $4.34 | +130.41% | 1 | Oct 10, 2023 | |
| SGMO Sangamo Therapeutics | Maintains: Outperform | $16 → $10 | $0.54 | +1,738.91% | 3 | Aug 11, 2023 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $73 → $70 | $83.33 | -16.00% | 6 | Aug 1, 2023 |
MoonLake Immunotherapeutics
Mar 13, 2024
Reiterates: Outperform
Price Target: $92
Current: $42.84
Upside: +114.75%
ARS Pharmaceuticals
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $9.33
Upside: +103.64%
Aquestive Therapeutics
Mar 7, 2024
Maintains: Outperform
Price Target: $4 → $9
Current: $3.37
Upside: +167.46%
Gossamer Bio
Mar 6, 2024
Reiterates: Outperform
Price Target: $6
Current: $0.71
Upside: +748.06%
Oculis Holding AG
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $12.85
Upside: +125.68%
REGENXBIO
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $16.20
Upside: +29.63%
Sarepta Therapeutics
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $130.90
Upside: +71.12%
Pacira BioSciences
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $26.95
Upside: +111.50%
Ascendis Pharma
Feb 8, 2024
Maintains: Outperform
Price Target: $207 → $225
Current: $141.01
Upside: +59.56%
Rani Therapeutics Holdings
Feb 6, 2024
Reiterates: Outperform
Price Target: $8
Current: $6.37
Upside: +25.59%
Liquidia
Dec 21, 2023
Reiterates: Underperform
Price Target: $3
Current: $13.17
Upside: -77.22%
Unity Biotechnology
Nov 16, 2023
Upgrades: Outperform
Price Target: n/a
Current: $1.56
Upside: -
Keros Therapeutics
Nov 13, 2023
Reiterates: Outperform
Price Target: $86
Current: $57.72
Upside: +49.00%
Immunic
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $1.30
Upside: +438.46%
MannKind
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $4.34
Upside: +130.41%
Sangamo Therapeutics
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.54
Upside: +1,738.91%
BioMarin Pharmaceutical
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $83.33
Upside: -16.00%